Comparison of Relapse Rates in Multiple Sclerosis Patients Switching from Glatiramer Acetate (Copaxone) to Fingolimod (Gilenya) versus Those Remaining on Glatiramer Acetate: STUDY
To compare relapse rates in multiple sclerosis (MS) patients switching from glatiramer acetate (GA) to fingolimod (FTY) versus those continuing treatment with GA.
Given the growing number of DMTs available for treatment of relapsing-remitting MS (RRMS), evidence generation to inform the use of individual agents and their treatment patterns is increasingly important.
A retrospective study was conducted using MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases. MS patients (蠅1 claim ICD-9=340) treated with GA in the 12 months prior to their first prescription of the DMT of interest (pre-period) during 1/1/2010-9/30/2012 were identified and assigned to the treatment group is they switched to FTY or the control group if they remained on GA (GA→FTY versus GA only, respectively). Both groups were followed for twelve months (post-period). Demographics, clinical characteristics, and medication use were assessed in the pre-period. Analyses of trends and difference-in-differences (DD) were applied to evaluate relapse rates by group. Odds ratio of relapse between groups was estimated using logistic regression.
6,779 patients were included (GA only=6,416; GA→FTY=363). Significant differences were observed between groups in age, geographic region, non-DMT medication utilization, MS-related symptoms, and proportion of days covered. A decline in the percentage of relapses occurred in both groups in the post- versus pre-periods (GA→FTY=16.2[percnt]; GA only=2.5[percnt]). DD analyses indicated a 13.7[percnt] relapse rate reduction associated with GA→FTY versus GA only. Comparing the pre-period and the post-period, the odds of relapse was 2.63 and 1.22 respectively for GA→FTY versus GA only.
Compared with patients remaining on GA, patients switching from GA to FTY demonstrated significant reductions in relapses over the 1-year timeframe. Characterization of key factors when considering a switch from GA to FTY is essential to informing appropriate treatment. Study Supported by: Novartis, KMK Consulting
Story Source: The above story is based on materials provided by NEUROLOGY
Note: Materials may be edited for content and length